NEW YORK (GenomeWeb News) – BG Medicine has filed a preliminary prospectus with the US Securities and Exchange Commission for a proposed initial public offering.

Though the biomarker-development firm did not disclose a price range for shares in the offering, or the anticipated number of shares it will offer, it said that the proposed maximum funds it would seek to raise is a little more than $86 million. BG has proposed that its stock trade on the Nasdaq Global Market under ticker symbol "BGMD."

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Magdalena Skipper, the incoming editor-in-chief of Nature, speaks with NPR's Weekend Edition Sunday.

Genetic genealogy has led to an arrest in another cold case, dating back to 1987.

In PLOS this week: mutation in second gene widens clinical symptoms of people with ADD3 mutations, comparative genomic analysis of Pseudovibrio, and more.

Wired reports that 23andMe is trying to bolster its outside collaborations.

Jun
19
Sponsored by
ACD

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.